Catheter Precision, Inc. Addresses Increased Trading Activity in Common Stock
Stock Trading Activity: Catheter Precision, Inc. has addressed recent increases in its stock trading activity, stating that it is unaware of any specific operational developments causing this surge.
Strategic Plans and Financing: The company reaffirmed its commitment to its strategic plans, including ongoing efforts to secure financing to meet its liquidity needs.
Trade with 70% Backtested Accuracy
Analyst Views on VTAK
About VTAK
About the author
VTAK Terminates ATM Equity Offering Program to Strengthen Balance Sheet
- Termination of Financing Plan: Catheter Precision has announced the termination of its ATM equity offering program, with no future equity lines of credit or forward-priced agreements anticipated, thereby eliminating financing burdens and enhancing financial stability.
- Strategic Financing Completed: The company has secured up to $36.5 million in a financing transaction with institutional investors aimed at supporting accelerated growth, significantly strengthening its capital structure and liquidity.
- Debt Structure Optimization: The company has converted short-term notes into long-term debt, extending maturities to two and three years, while approximately $9 million in short and long-term liabilities are being converted into equity, further improving its financial position.
- Strengthened Growth Strategy: This strategic investment provides the company with financial flexibility to advance key growth initiatives, expand market presence, and enhance execution capabilities, thereby creating long-term value for shareholders.
Catheter Precision Implements LockeT at Ireland's Largest EP Center
- Global Expansion Milestone: Catheter Precision successfully implements LockeT at Mater Private Hospital in Ireland, marking a significant advancement in the company's global expansion strategy while enhancing procedural safety and efficiency in cardiac care.
- Key Partnership: As Ireland's largest electrophysiology center performing over 1,000 procedures annually, Mater Private's adoption of LockeT will significantly enhance innovation in arrhythmia treatment.
- Rapid Training and Adoption: The chief nurse trained 52 staff members in just two days, showcasing LockeT's intuitive design and operational efficiency, which ensures swift adoption of the device.
- Market Validation: The European Sales Manager highlighted that Mater Private's multi-year commitment to LockeT validates the technology's value and strengthens Catheter Precision's position in the global electrophysiology market.
Catheter Precision Launches LockeT Device in Switzerland with Positive Clinical Outcomes
- Successful Product Launch: Catheter Precision has successfully launched its LockeT suture retention device in Switzerland, with the first clinical cases performed at Spitalzentrum Biel yielding excellent procedural outcomes and positive feedback from clinical and nursing teams, marking a significant technological advancement in the cardiac electrophysiology market.
- Strategic Distribution Agreement: The partnership with FuMedica AG, a leading Swiss medical device distributor, enables rapid introduction of LockeT to hospitals and clinics across Switzerland, further expanding Catheter Precision's footprint in the European market.
- Cost Efficiency Improvement: The intuitive design of the LockeT device not only reduces groin management costs but also supports same-day discharge, enhancing the overall patient experience and demonstrating its potential application in cardiac interventional procedures.
- Global Market Expansion: With over 10,000 LockeTs shipped globally to date, Catheter Precision is actively expanding its business in the rapidly growing cardiac electrophysiology market, working diligently with partners to improve patient treatment outcomes.
Catheter Precision (VTAK) Announces Q3 and Year-to-Date Results for 2025
Financial Performance: Catheter Precision, Inc. reported a 135% increase in Q3 2025 revenue to $226,000 compared to Q3 2024, with a total revenue of $581,000 for the first nine months of 2025, up 114% from the previous year. The GAAP net loss for Q3 2025 was reduced by 45% to $2,251,000.
Product Expansion: The company is experiencing increased sales activity for its products, LockeT and VIVO, particularly in international markets following CE Mark approvals, with notable interest from countries like Germany, France, and South Africa.
Clinical Studies and Market Position: Catheter Precision emphasizes the importance of clinical studies, with recent publications highlighting the economic benefits of its products. CEO David Jenkins expressed confidence in the company's growth potential and the transformative impact of VIVO on treating ventricular arrhythmias.
Forward-Looking Statements: The company cautions that its projections and expectations regarding growth and product expansion are subject to various risks and uncertainties, including regulatory challenges, market acceptance, and financial stability.
3 Penny Stocks to Keep an Eye On as of August 19, 2025
Penny Stocks to Watch: Soligenix, Catheter Precision, and Wellgistics Health are highlighted as penny stocks to monitor on August 19, 2025, based on their performance metrics from TipRanks’ Penny Stock Screener.
Soligenix (SNGX): This biopharmaceutical company saw a significant stock price increase of 78% after receiving orphan drug designation from the FDA for its treatment of Behcet’s Disease, resulting in a Dollar Volume of $914.44 million.
Catheter Precision (VTAK): The medical device company experienced a stock surge of over 62% following the approval of its LockeT device in the UK, leading to a Dollar Volume of $254.58 million.
Wellgistics Health (WGRX): The healthcare technology firm reported a nearly 21% rise in stock price due to positive news regarding its equity line termination and the launch of a blockchain payment program, achieving a Dollar Volume of $67.66 million.
Palo Alto Shares Rise Approximately 7%; Check Out 20 Stocks Making Moves in Premarket Trading
Palo Alto Networks Financial Performance: Palo Alto Networks, Inc. reported strong financial results for Q4 of fiscal 2025, with revenue increasing by 16% year-over-year to $2.54 billion and adjusted earnings per share at 95 cents, surpassing analyst expectations.
Stock Movement: Following the positive earnings report, shares of Palo Alto Networks rose by 6.6% in pre-market trading, reaching $187.81.
Other Pre-Market Stock Movements: Several stocks experienced significant changes in pre-market trading, including Laser Photonics Corp, which surged 65.5%, and Color Star Technology Co Ltd, which gained 60.3%.
Declining Stocks: Conversely, some stocks saw declines, such as ALX Oncology Holdings Inc, which fell 19%, and Soligenix, Inc., which dipped 16.7% after previous gains.
VTAK Terminates ATM Equity Offering Program to Strengthen Balance Sheet
- Termination of Financing Plan: Catheter Precision has announced the termination of its ATM equity offering program, with no future equity lines of credit or forward-priced agreements anticipated, thereby eliminating financing burdens and enhancing financial stability.
- Strategic Financing Completed: The company has secured up to $36.5 million in a financing transaction with institutional investors aimed at supporting accelerated growth, significantly strengthening its capital structure and liquidity.
- Debt Structure Optimization: The company has converted short-term notes into long-term debt, extending maturities to two and three years, while approximately $9 million in short and long-term liabilities are being converted into equity, further improving its financial position.
- Strengthened Growth Strategy: This strategic investment provides the company with financial flexibility to advance key growth initiatives, expand market presence, and enhance execution capabilities, thereby creating long-term value for shareholders.
Catheter Precision Implements LockeT at Ireland's Largest EP Center
- Global Expansion Milestone: Catheter Precision successfully implements LockeT at Mater Private Hospital in Ireland, marking a significant advancement in the company's global expansion strategy while enhancing procedural safety and efficiency in cardiac care.
- Key Partnership: As Ireland's largest electrophysiology center performing over 1,000 procedures annually, Mater Private's adoption of LockeT will significantly enhance innovation in arrhythmia treatment.
- Rapid Training and Adoption: The chief nurse trained 52 staff members in just two days, showcasing LockeT's intuitive design and operational efficiency, which ensures swift adoption of the device.
- Market Validation: The European Sales Manager highlighted that Mater Private's multi-year commitment to LockeT validates the technology's value and strengthens Catheter Precision's position in the global electrophysiology market.
Catheter Precision Launches LockeT Device in Switzerland with Positive Clinical Outcomes
- Successful Product Launch: Catheter Precision has successfully launched its LockeT suture retention device in Switzerland, with the first clinical cases performed at Spitalzentrum Biel yielding excellent procedural outcomes and positive feedback from clinical and nursing teams, marking a significant technological advancement in the cardiac electrophysiology market.
- Strategic Distribution Agreement: The partnership with FuMedica AG, a leading Swiss medical device distributor, enables rapid introduction of LockeT to hospitals and clinics across Switzerland, further expanding Catheter Precision's footprint in the European market.
- Cost Efficiency Improvement: The intuitive design of the LockeT device not only reduces groin management costs but also supports same-day discharge, enhancing the overall patient experience and demonstrating its potential application in cardiac interventional procedures.
- Global Market Expansion: With over 10,000 LockeTs shipped globally to date, Catheter Precision is actively expanding its business in the rapidly growing cardiac electrophysiology market, working diligently with partners to improve patient treatment outcomes.
Catheter Precision (VTAK) Announces Q3 and Year-to-Date Results for 2025
Financial Performance: Catheter Precision, Inc. reported a 135% increase in Q3 2025 revenue to $226,000 compared to Q3 2024, with a total revenue of $581,000 for the first nine months of 2025, up 114% from the previous year. The GAAP net loss for Q3 2025 was reduced by 45% to $2,251,000.
Product Expansion: The company is experiencing increased sales activity for its products, LockeT and VIVO, particularly in international markets following CE Mark approvals, with notable interest from countries like Germany, France, and South Africa.
Clinical Studies and Market Position: Catheter Precision emphasizes the importance of clinical studies, with recent publications highlighting the economic benefits of its products. CEO David Jenkins expressed confidence in the company's growth potential and the transformative impact of VIVO on treating ventricular arrhythmias.
Forward-Looking Statements: The company cautions that its projections and expectations regarding growth and product expansion are subject to various risks and uncertainties, including regulatory challenges, market acceptance, and financial stability.
3 Penny Stocks to Keep an Eye On as of August 19, 2025
Penny Stocks to Watch: Soligenix, Catheter Precision, and Wellgistics Health are highlighted as penny stocks to monitor on August 19, 2025, based on their performance metrics from TipRanks’ Penny Stock Screener.
Soligenix (SNGX): This biopharmaceutical company saw a significant stock price increase of 78% after receiving orphan drug designation from the FDA for its treatment of Behcet’s Disease, resulting in a Dollar Volume of $914.44 million.
Catheter Precision (VTAK): The medical device company experienced a stock surge of over 62% following the approval of its LockeT device in the UK, leading to a Dollar Volume of $254.58 million.
Wellgistics Health (WGRX): The healthcare technology firm reported a nearly 21% rise in stock price due to positive news regarding its equity line termination and the launch of a blockchain payment program, achieving a Dollar Volume of $67.66 million.
Palo Alto Shares Rise Approximately 7%; Check Out 20 Stocks Making Moves in Premarket Trading
Palo Alto Networks Financial Performance: Palo Alto Networks, Inc. reported strong financial results for Q4 of fiscal 2025, with revenue increasing by 16% year-over-year to $2.54 billion and adjusted earnings per share at 95 cents, surpassing analyst expectations.
Stock Movement: Following the positive earnings report, shares of Palo Alto Networks rose by 6.6% in pre-market trading, reaching $187.81.
Other Pre-Market Stock Movements: Several stocks experienced significant changes in pre-market trading, including Laser Photonics Corp, which surged 65.5%, and Color Star Technology Co Ltd, which gained 60.3%.
Declining Stocks: Conversely, some stocks saw declines, such as ALX Oncology Holdings Inc, which fell 19%, and Soligenix, Inc., which dipped 16.7% after previous gains.
